Your Messages Inbox
Your Article Summary
See Latest ArticlesNovartis receives Complete Response letter from FDA for QAB149, an investigational bronchodilator for COPD
Novartis, 10/20/09
Novartis has received a Complete Response letter from the US Food and Drug Administration as part of the US regulatory review for QAB149, an investigational once–daily bronchodilator for the treatment of adult patients with chronic obstructive pulmonary disease.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis receives approval in the European Union for Onbrez Breezhaler, a new once-daily bronchodilator for patients with COPD
Novartis, 12/04/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09
Article Search
Sponsor